AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 91 min read$RMD

Farrell Michael J. sold $968K of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $193.96 ($0.97M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Jun 9, 2026, 6:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RMD
Neutral
medium confidence
Mentioned
$RMD
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

The newest fact is the CEO/chairman’s open-market sale amount and execution date, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but 10b5-1 sales usually carry limited fundamental information.

03

What to watch

Check whether there were multiple consecutive insider sales or changes in trading patterns; a single 10b5-1 sale is often statistically noisy.

Relevance 4/10Novelty 5/10Timing: filed June 9; sale executed June 8

Background

The article is an SEC Form 4 insider transaction disclosure for ResMed (RMD).

Company-level read

Ticker impact

$RMDNeutralMedium confidence
Context

ResMed insider Form 4 shows CEO/chairman Michael Farrell sold 4,991 shares for ~$968K on a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect should be short-lived unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan and provides no new operational/regulatory information.

Market effects

Sector

No direct sector read-through; this is company-specific insider liquidity/positioning.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect scheduled diversification rather than bearish expectations; traders may ignore it absent follow-on selling or fundamentals.

Key entities

  • issuer
    ResMed Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Farrell Michael J.

    Chairman and CEO who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 9
$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.

thebull.com.au6 min
AUG 9
$RMDHighAI 9/10

ResMed Q4 Earnings Call Highlights

ResMed (NYSE:RMD) reported Q4 non-GAAP gross margin up 90 bps to 62.3% YoY, citing productivity and supply-chain efficiency, but down ~50 bps sequentially due to higher component and freight costs and a ~20-bp FX headwind. The company set a $42M Astral field safety provision and guided FY2027 reported revenue $5.75B-$5.85B and non-GAAP EPS $12.00-$12.25, plus $1.5B buybacks and a 10% dividend increase.

finance.yahoo.com6 min
AUG 7
$RMDMedAI 8/10

Why is ResMed stock sliding today?

ResMed shares fell about 5.5% pre-open after the company reported mixed Q4 FY2026 results. Non-GAAP EPS was $2.95, above the ~$2.89 consensus, but revenue was $1.46B, slightly below ~$1.47B. ResMed’s first full-year FY2027 guidance implied 5–7% core revenue growth, plus a $75M Astral ventilator safety headwind, with MatrixCare divestiture and Noctrix acquisition expected to dilute EPS. Analysts cut price targets.

investing.com4 min
AUG 7
$RMDMed

CPAP machine maker posts record revenue but shares sink

ResMed, an ASX-listed CPAP maker, reported record Q4 revenue of US$1.5B and FY2025/26 revenue of US$5.7B, up 10%. Full-year net income rose 9% to US$1.5B, but gross margin was 62.3% versus 62.7% expected, which the company attributed to inflation. ResMed plans modest 2026/27 price increases. Shares fell 4.9% to $29.94.

perthnow.com.au4 min
AUG 6
$RMDMedAI 9/10

RESMED INC (RMD): Results of Operations and Financial Condition

RESMED INC (RMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d158732dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 investorrelations@resmed.com news@resmed.com Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 • Q4 revenue increased by 9% to a record $1.5 bil

SEC EDGAR 8-K6 min